GlassScriptPhysician profile
Larry C Johnson
NPI 1285653618
$7,602.40
in general payments reported to CMS, 2019-2025
37 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $399 · 2021: $813 · 2022: $1,211 · 2023: $1,372 · 2024: $1,167 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,214.34 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,136.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $898.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $789.16 | 2021-2025 | |
| Amgen INC. | $489.15 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.29 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $339.30 | 2019-2022 | |
| Novo Nordisk INC | $271.74 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $256.02 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.04 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $200.85 | 2019-2022 | |
| Exact Sciences Corporation | $179.68 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $142.92 | 2019-2022 | |
| Abbott Laboratories | $138.29 | 2021-2025 | Freestyle Libre 2, Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.91 | 2024-2025 | Caplyta |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.